Replies to post #142938 on Biotech Values

[genisi]

I have high hopes for the anti PD-1 class not only from the scientific point of view but also since a friend has been enrolled to the CureTech/CT-011 phase II metastatic melanoma clinical trial.

[genisi]

One more important detail on BMS-936558, BMY’s anti-PD-1 cancer drug:

Preliminary data implicate PD-L1 expression on tumor cells as a potential predictive biomarker of response

http://abstract.asco.org/AbstView_114_91353.html